The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Intra-Cellular Therapies, Inc.’s lumateperone for the treatment of schizophrenia.  The action was requested based on clinical evidence that the drug has the potential to successfully treat schizophrenia along with with significant improvements on several safety issues, including metabolic, motor and cardiovascular conflicts associated with many current antipsychotic agents.     The FDA’s Fast Track designa...